Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Hodgson, Susanne H ^a   Juma, Elizabeth ^b,c   Salim, Amina ^b   Magiri, Charles ^b   Njenga, Daniel ^b   Molyneux, Sassy ^b   Njuguna, Patricia ^b   Awuondo, Ken ^b   Lowe, Brett ^b   Billingsley, Peter F ^d   Cole, Andrew O ^b,c   Ogwang, Caroline ^b   Osier, Faith ^b   Chilengi, Roma ^e   Hoffman, Stephen L ^d   Draper, Simon J ^a   Ogutu, Bernhards ^b,c   Marsh, Kevin ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c STRATHMORE UNIVERSITY   (Kenya)

^d SANARIA INC   (United States)

^e CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

Author keywords

African; Challenge; CHMI; Drug; Kenya; Lessons; Malaria; PfSPZ Challenge; Plasmodium falciparum; Vaccine

Indexed keywords

MALARIA VACCINE;

ADOLESCENT; ADULT; AFRICA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; HUMAN; INTERVENTION STUDY; KENYA; KENYAN; MALARIA; OPEN STUDY; PILOT STUDY; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; SPOROZOITE; DOSE RESPONSE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALARIA, FALCIPARUM; MALE; PARASITOLOGY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; KENYA; MALARIA, FALCIPARUM; MALE; PILOT PROJECTS; PLASMODIUM FALCIPARUM; SPOROZOITES; YOUNG ADULT;

EID: 84928621655     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0671-x     Document Type: Article

References (33)

1. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11:57-64.
2. Roestenberg M, de Vlas SJ, Nieman AE, Sauerwein RW, Hermsen CC. Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. J Infect Dis. 2012;206:319-23.
3. Pollard AJ, Savulescu J, Oxford J, Hill AV, Levine MM, Lewis DJ, et al. Human microbial challenge: the ultimate animal model. Lancet Infect Dis. 2012;12:903-5.
4. Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg. 2012;86:561-5.
5. Engwerda CR, Minigo G, Amante FH, McCarthy JS. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 2012;28:515-21.
6. Spring M, Polhemus M, Ockenhouse C. Controlled human malaria infection. J Infect Dis. 2014;209 Suppl 2:S40-5.
7. Chilengi R. Clinical development of malaria vaccines: should earlier trials be done in malaria endemic countries? Hum Vaccin. 2009;5:627-36.
8. Sheehy SH, Douglas AD, Draper SJ. Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother. 2013;9:1831-40.
9. Epstein JE. Taking a bite out of malaria: controlled human malaria infection by needle and syringe. Am J Trop Med Hyg. 2013;88:3-4.
10. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2013;88:5-13.
11. Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One. 2013;8, e65960.
12. Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James E, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91:471-80.
13. Hodgson SH, Juma E, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686.
14. Laurens MB, Duncan CJ, Epstein JE, Hill AV, Komisar JL, Lyke KE, et al. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine. 2012;30:5302-4.
15. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, Stalenhoef A, et al. Cardiac complication after experimental human malaria infection: a case report. Malar J. 2009;8:277.
16. van Meer MP, Bastiaens GJ, Boulaksil M, de Mast Q, Gunasekera A, Hoffman SL, et al. Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. Malar J. 2014;13:38.
17. Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis. 2007;196:145-54.
18. Roestenberg M, O'Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, et al. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One. 2012;7, e38434.
19. Dickert N, Sugarman J. Ethical goals of community consultation in research. Am J Public Health. 2005;95:1123-7.
20. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:457-68.
21. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. BMJ. 1954;1:290-4.
22. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol. 2008;9:725-32.
23. CDC: Malaria information and prophylaxis by country. 2014. www.cdc.gov/malaria/travelers/country-table/a.html.
24. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, Carneiro I, et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A. 2005;102:5108-13.
25. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg. 1989;83:293-303.
26. Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine. 2006;24:4233-46.
27. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008;76:2240-8.
28. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One. 2008;3, e3571.
29. Edstein MD, Kotecka BM, Anderson KL, Pombo DJ, Kyle DE, Rieckmann KH, et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother. 2005;49:4421-2.
30. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20:2355-68.
31. Nikolaeva D, Draper SJ, Biswas S. Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vaccines 2015:1-28. epublished ahead of print.
32. Liljander A, Wiklund L, Falk N, Kweku M, Martensson A, Felger I, et al. Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malar J. 2009;8:78.
33. Mordmüller B, Suppan C, Sim KL, Gómez-Pe rez G, Salazar CLO, Held J, et al. 2015. Malar J. 18;14(1):117. doi:10.1186/s12936-015-0628-0.